PAR 1.00% $1.48 paradigm biopharmaceuticals limited..

Ann: Trading Halt, page-54

  1. 26 Posts.
    lightbulb Created with Sketch. 4
    I suppose your question is one for the BOD and management. That is, are the results that positive on efficacy, that a pivot in strategy is in the shareholders best interests? You seem to think so which is great.

    I still think PAR needs to clarify the pivot. IMHO, the lack of interest in a deal on the P2 data is material to the SP.
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Mkt cap ! $284.4M
Open High Low Value Volume
$1.50 $1.51 $1.48 $391.9K 262.5K

Buyers (Bids)

No. Vol. Price($)
3 2616 $1.48

Sellers (Offers)

Price($) Vol. No.
$1.50 7565 3
View Market Depth
Last update - 16.10pm 24/05/2019 (20 minute delay) ?
-0.015 ( 1.00 %)
Open High Low Volume
$1.49 $1.51 $1.48 32445
Last updated 15.59pm 24/05/2019 (live) ?
PAR (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.